Full video transcriptClick to expand
Auto-generated transcript of @genxshopfinds76's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Okay, I'm going to talk about Tessa Fensin because she's asking about it.
- 0:02I have not personally prescribed it yet or used it, but I did look a little more into it.
- 0:07So some people use it for weight loss, but it's not a GLP1, but it's a triple reuptake
- 0:12inhibitor.
- 0:13So it boosts like dopamine, nor epinephrine and serotonin.
- 0:17It was originally studied for like Alzheimer's and Parkinson's patients and trials, but what
- 0:21they noticed is people were losing weight with it, like a lot of it, like 10% of their body
- 0:26weight in six months.
- 0:28So it's now being explored more off label for weight loss, energy and focus.
- 0:33So people report less hunger, better mood and more motivation without that GLP1 fatigue
- 0:40or nausea.
- 0:41But there's a catch.
- 0:42It is definitely not FDA-approved yet for weight loss and they are noticing things like
- 0:46heart rate and blood pressure effects.
- 0:48So always keep a close eye on that and work with your doctor on that.
- 0:52I don't prescribe it yet, but I'm just sharing the science around it.
- 0:56Mass-afferencing, you know, could give more of a brain boost and appetite control.
- 1:00Maybe it will be your GLP alternative.
- 1:02I'm not 100% sure.
- 1:03Like I said, I have not personally prescribed it or used it, but it looks like it has some
- 1:08promising effects.
- 1:09Thank you.
Tesofensine for weight loss: what the trials actually show
Quick answer
Tesofensine is a monoamine reuptake inhibitor with Phase 2 data showing approximately 10% body weight reduction over 24 weeks at 1 mg daily, but it has no FDA-approved indication and no completed Phase 3 trial in a major regulatory market. Its mechanism of action, dopamine, norepinephrine, and serotonin reuptake inhibition, produces clinically meaningful cardiovascular effects including elevated resting heart rate and increased blood pressure that require active monitoring. It should not be characterized as a straightforward alternative to GLP-1 receptor agonists given the asymmetry in available safety and efficacy data.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tesofensine for weight loss: what the trials actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Tesofensine for weight loss: what the trials actually show is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tesofensine for weight loss: what the trials actually show" from GenXshopfinds. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tesofensine is a monoamine reuptake inhibitor with Phase 2 data showing approximately 10% body weight reduction over 24 weeks at 1 mg daily, but it has no FDA-approved indication and no completed Phase 3 trial in a major regulatory market.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to kelsey forcier tesofensine the triple reuptake i." In this clip, the useful excerpt is: "Okay, I'm going to talk about Tessa Fensin because she's asking about it." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tesofensine is a monoamine reuptake inhibitor with Phase 2 data showing approximately 10% body weight reduction over 24 weeks at 1 mg daily, but it has no FDA-approved indication and no completed Phase 3 trial in a major regulatory market.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tesofensine is a monoamine reuptake inhibitor with Phase 2 data showing approximately 10% body weight reduction over 24 weeks at 1 mg daily, but it has no FDA-approved indication and no completed Phase 3 trial in a major regulatory market. Its mechanism of action, dopamine, norepinephrine, and serotonin reuptake inhibition, produces clinically meaningful cardiovascular effects including elevated resting heart rate and increased blood pressure that require active monitoring. It should not be characterized as a straightforward alternative to GLP-1 receptor agonists given the asymmetry in available safety and efficacy data.
- The only major published efficacy trial (Astrup et al., 2008, Lancet) enrolled 203 patients and lasted 24 weeks. There are no Phase 3 or long-term cardiovascular outcomes data.
- Tesofensine has no FDA-approved indication and no active NDA on public record as of early 2025. It is not in a standard approval pipeline the way the video's 'not FDA-approved yet' framing implies.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The only major published efficacy trial (Astrup et al., 2008, Lancet) enrolled 203 patients and lasted 24 weeks. There are no Phase 3 or long-term cardiovascular outcomes data.
- Tesofensine has no FDA-approved indication and no active NDA on public record as of early 2025. It is not in a standard approval pipeline the way the video's 'not FDA-approved yet' framing implies.
- Average resting heart rate increased by roughly 7-8 bpm in the Astrup trial at the 1 mg dose. For anyone with hypertension, arrhythmia history, or cardiovascular risk factors, that is a clinically significant concern.
- The triple reuptake inhibitor mechanism is chemically distinct from GLP-1 receptor agonism. These compounds work through fundamentally different pathways and should not be treated as interchangeable alternatives.
- Any tesofensine obtained outside a clinical trial in the U.S. is likely sourced from compounding pharmacies or international suppliers with no regulatory oversight over purity, dose accuracy, or contamination.
- The creator's transparency about not having prescribed it and advising physician oversight is appropriate. That caveat deserves more weight than the optimistic framing around appetite control and mood benefits.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @genxshopfinds76 actually say?
The creator described tesofensine as a "triple reuptake inhibitor" that boosts dopamine, norepinephrine, and serotonin, originally studied for neurological conditions before researchers noticed significant weight loss in trial participants. They cited roughly 10% body weight loss over six months, flagged cardiovascular side effects, and were transparent that it is not FDA-approved and that they have not personally prescribed it.
Credit where it's due: this is more careful than most TikTok weight loss content. The creator explicitly said "I have not personally prescribed it yet or used it," warned about heart rate and blood pressure effects, and avoided making direct treatment recommendations. The framing is exploratory rather than promotional, which is the right posture for an unapproved compound with limited long-term safety data.
Does the science back this up?
Mostly, yes, but the picture is more complicated than the video suggests. The 10% body weight figure is real but comes from a small, short-duration trial, and the compound has faced regulatory setbacks that the creator did not mention.
The most-cited early data comes from Astrup et al. (2008, Lancet), a Phase 2 trial in 203 patients with obesity. At the 1 mg dose, participants lost a mean of about 10.6% of body weight over 24 weeks versus roughly 2% for placebo. That is a real and striking effect. However, the trial was stopped by the sponsor, NeuroSearch, and subsequent Phase 3 development stalled, partly due to cardiovascular signals including elevated heart rate and blood pressure, exactly what the creator flagged. A follow-up analysis by Sjödin et al. (2010, Obesity Reviews) confirmed the appetite-suppressing mechanism is primarily monoamine reuptake inhibition, consistent with the triple reuptake inhibitor description.
What did they get wrong (or right)?
The mechanism description is accurate. The weight loss number checks out against published data. The cardiovascular warning is appropriate and important. Where the video falls short is in omitting context that would genuinely matter to someone considering this compound.
First, tesofensine never completed Phase 3 trials in a major regulatory jurisdiction. It is not just "not FDA-approved yet" as if approval is pending. There is no active FDA New Drug Application on record as of early 2025. The "yet" implies a pipeline that does not clearly exist at scale. Second, the comparison to GLP-1 side effects is under-supported. The creator suggests tesofensine avoids "GLP-1 fatigue or nausea," but the Astrup trial recorded increased heart rate of roughly 7-8 bpm on average, insomnia, dry mouth, and nausea in a meaningful proportion of participants. Trading one side effect profile for another is not the same as having fewer side effects. Third, describing current use as "off-label" is technically imprecise. Off-label use applies to approved drugs used outside their label. Tesofensine has no approved indication anywhere, so prescribing it in most contexts would involve compounded or research-grade material, which carries different risk and legal considerations entirely.
What should you actually know?
Tesofensine is a real compound with real early-phase weight loss data, but it is not a waiting-room version of semaglutide. The mechanism is genuinely different, the regulatory situation is genuinely unresolved, and the cardiovascular concerns are not minor caveats.
Anyone seeing this video and searching for a prescriber should understand the following: the compound acts on the same monoamine system as older stimulant-class drugs, which means cardiovascular monitoring is not optional, it is mandatory. The Astrup 2008 data is promising but involves fewer than 200 patients followed for six months. There are no published 2-year cardiovascular outcomes data comparable to what exists for semaglutide. Researchers including Rasmussen et al. have explored reformulations and combination approaches, but none have reached late-stage regulatory review. If someone is obtaining this through a compounding pharmacy or overseas supplier, they are operating in a space with essentially no regulatory oversight over what they are actually receiving. The creator is right to say "work with your doctor on that." That advice should be taken seriously, not treated as a liability disclaimer.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
GenXshopfinds · TikTok creator
7.6K views on this video
Replying to @Kelsey Forcier Tesofensine: the triple reuptake inhibitor turning heads in weight loss research. Not a GLP-1, but definitely on the radar. 🧠🔥 *not medical advice
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the only major published efficacy trial (astrup et al., 2008,?
The only major published efficacy trial (Astrup et al., 2008, Lancet) enrolled 203 patients and lasted 24 weeks. There are no Phase 3 or long-term cardiovascular outcomes data.
What does the video say about tesofensine has no fda-approved indication?
Tesofensine has no FDA-approved indication and no active NDA on public record as of early 2025. It is not in a standard approval pipeline the way the video's 'not FDA-approved yet' framing implies.
What does the video say about average resting heart rate increased by roughly 7-8 bpm in?
Average resting heart rate increased by roughly 7-8 bpm in the Astrup trial at the 1 mg dose. For anyone with hypertension, arrhythmia history, or cardiovascular risk factors, that is a clinically significant concern.
What does the video say about the triple reuptake inhibitor mechanism?
The triple reuptake inhibitor mechanism is chemically distinct from GLP-1 receptor agonism. These compounds work through fundamentally different pathways and should not be treated as interchangeable alternatives.
What does the video say about any tesofensine obtained outside a clinical trial in the u.s.?
Any tesofensine obtained outside a clinical trial in the U.S. is likely sourced from compounding pharmacies or international suppliers with no regulatory oversight over purity, dose accuracy, or contamination.
What does the video say about the creator's transparency about not having prescribed it?
The creator's transparency about not having prescribed it and advising physician oversight is appropriate. That caveat deserves more weight than the optimistic framing around appetite control and mood benefits.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by GenXshopfinds, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.